TUSC2 gene therapy in KRASG12C mutant NSCLC overcomes acquired resistance to sotorasib

被引：0
|
作者：
Meraz, I. [1 ]
Majidi, M. [1 ]
Gao, L. [1 ]
Ren, C. [1 ]
Wu, S. [1 ]
Song, R. [1 ]
Meng, F. [1 ]
Xu, Y. [1 ]
Wang, Q. [2 ]
Xi, Y. [2 ]
Wang, J. [2 ]
Jung, S. Y. [3 ]
Shpall, E. [4 ]
Roth, J. A. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Thorac & Cardiovasc Surg, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Bioinformat & Computat Biol, Houston, TX 77030 USA
[3] Baylor Coll Med, Biochem, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Stem Cell Transplantat, Houston, TX 77030 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114897
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB372
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [31] RMC-4630, a SHP2 Inhibitor, in Combination with Sotorasib for Advanced KRASG12C NSCLC After Failure of Prior Standard Therapies: A Phase 2 Trial
    Johnson, M. L.
    Langdon, R.
    Ellison, D.
    Spira, A.
    Amin, H.
    Castine, M.
    Daniel, D.
    Larson, T.
    Sohoni, S.
    Chen, Y. C.
    Hayes, J.
    Yang, L.
    Masciari, S.
    Wang, X.
    Toya, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S454 - S455
  • [32] Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer
    Chour, A.
    Denis, J.
    Lafitte, C.
    Mascaux, C.
    Zysman, M.
    Lemaitre, A.
    Swalduz, A.
    Gounant, V.
    Cortot, A.
    Darrason, M.
    Cadranel, J.
    Auclin, E.
    Basse, C.
    Tissot, C.
    Decroisette, C.
    Bombaron, P.
    Giroux-Leprieur, E.
    Falchero, L.
    Lebosse, F.
    Duruisseaux, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S49 - S50
  • [33] Acquired resistance to KRASG12C inhibitors evolves from drug tolerant cells vulnerable to AsiDNA.
    Jdey, Wael
    Dubois, Aurelie
    Ratel, Loane
    Lienafa, Marie-Christine
    Trochon-Joseph, Veronique
    Bono, Francoise
    CANCER RESEARCH, 2021, 81 (13)
  • [34] Selective deletion of the KRAS mutant gene with ADGN-123 and ADGN-121 peptide-RNA nanoparticles: A new strategy to overcome acquired resistance to KRASG12C and KRASG12D small molecule inhibitors
    Divita, Gilles
    Grunenberger, Audrey
    Guzman-gonzalez, Veronica
    Czuba, Elodie
    Boularache, Khadidja
    Guidetti, Melanie
    Josserand, Veronique
    Desai, Neil
    CANCER RESEARCH, 2024, 84 (06)
  • [35] A next generation tri-complex KRASG12C(ON) inhibitor directly targets the active, GTP-bound state of mutant RAS and may overcome resistance to KRASG12C(OFF) inhibition.
    Nichols, Robert J.
    Cregg, Jim
    Schulze, Christopher J.
    Wang, Zhican
    Yang, Kevin
    Jiang, Jingjing
    Whalen, Daniel M.
    Hansen, Rich
    Garrenton, Lindsay S.
    Bermingham, Alun
    Knox, John E.
    Choy, Tiffany
    Reyes, Denise
    Rios, Mayra
    Seamon, Kyle
    Longhi, Michael
    Chou, Kang-Jye
    Li, Shaoling
    Wildes, David P.
    Singh, Mallika
    Koltun, Elena S.
    Gill, Adrian L.
    Smith, Jacqueline A. M.
    CANCER RESEARCH, 2021, 81 (13)
  • [36] The small molecule KRAS inhibitor, TEB-17231, blocks tumor progression and overcomes KRASG12C inhibitor mediated resistance
    Xu, Zusheng
    Weaver, David T.
    Drakas, Robert
    Lou, Yangtong
    CANCER RESEARCH, 2023, 83 (07)
  • [37] Comparison Between Sotorasib with Docetaxel for the Treatment of Chinese Patients with Previously Treated NSCLC with KRASG12C Mutation: A Cost-Effectiveness Analysis to Inform Drug Pricing
    Yi, Lidan
    Zeng, Xiaohui
    Zhou, Zhen
    Liu, Qiao
    ADVANCES IN THERAPY, 2024, 41 (08) : 3159 - 3172
  • [38] DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with the KRASG12C inhibitor sotorasib resulting in tumor regression in KRAS mutant NSCLC xenograft models
    McMahon, Martin
    Bogdan, Madhumita
    Timson, Mary J.
    Al-Hashimi, Hikmat
    Ghazi, Phaedra
    Zhan, Yu
    Smith, Bryan D.
    Kinsey, Conan G.
    Flynn, Daniel L.
    CANCER RESEARCH, 2022, 82 (12)
  • [39] Gene expression correlates of adagrasib response in KRASG12C mutated non-small cell lung cancer (NSCLC)
    Kim, Eejung
    Tong, Xinyuan
    Patel, Ayushi
    Liu, Shengwu
    Dilly, Julien
    Hover, Laura
    Mukhopadhyay, Suman
    Sherman, Fiona
    Christensen, James G.
    Olson, Peter
    Aguirre, Andrew
    Wong, Kwok
    Ji, Hongbin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C
    Zhuang, Haiming
    Fan, Jigang
    Li, Mingyu
    Zhang, Hao
    Yang, Xiuyan
    Lin, Ligen
    Lu, Shaoyong
    Wang, Qing
    Liu, Yaqin
    FRONTIERS IN ONCOLOGY, 2022, 12
12345